Edition:
United Kingdom

People: Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

539.00GBp
16 Sep 2019
Change (% chg)

-1.00 (-0.19%)
Prev Close
540.00
Open
540.00
Day's High
556.00
Day's Low
534.00
Volume
137,100
Avg. Vol
61,268
52-wk High
930.00
52-wk Low
534.00

Tallarigo, Lorenzo 

Dr. Lorenzo Tallarigo, M.D. has been appointed as Non-Executive Chairman of the Board of the Company, effective 1 February 2016. From 2008 to 2014 Dr.Tallarigo was a member of the Board, and Chairman from 2011, of Intercept Pharmaceuticals (Nasdaq:ICPT). Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat liver diseases. Intercept's NASDAQ IPO in 2012 was one of the most successful ever and today the company is valued at $3.7 billion. From 2009 to 2014, Dr. Tallarigo also held the position of Chief Executive Officer at Genextra, a holding company focused on identifying innovative research and projects in life sciences to develop novel treatments and tools by creating successful business ventures, including a 30 per cent. shareholding in Intercept Pharmaceuticals. Under his leadership at Genextra, where he continues as a current Board member, Dr. Tallarigo raised finance to support the activities of several healthcare companies acting in a variety of therapeutic areas. From 1985 to 2008, Dr. Tallarigo worked at Eli Lilly, where he held various positions in areas of clinical research, pharmaceutical product management and marketing and general management, and latterly as its President of international operations. During his latter role at Eli Lilly, Dr. Tallarigo was responsible for $8 billion of revenues and $4 billion in profits, covering 140 countries and managing 12,000 employees. Dr. Tallarigo was formerly a member of the board of trustees for the University of Indianapolis and a member of the international committee of the Indiana University Foundation. He has a Doctor of Medicine degree from the University of Pisa (Italy) and a PMD from Harvard Business School in Boston.

Basic Compensation

Total Annual Compensation, GBP 150,000
Restricted Stock Award, GBP --
Long-Term Incentive Plans, GBP --
All Other, GBP --
Fiscal Year Total, GBP 150,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --